,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2017', 'fs': 'Feb 2017', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw3rUAC'}, 'Id': 'a0P2P000007Dw3rUAC', 'Event_Date__c': '2017-02-13', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2017', 'Status_History__c': 'a132P000000ArFoQAK'}, 'change': None}]",Feb 2017,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2017', 'fs': 'Mar 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw3sUAC'}, 'Id': 'a0P2P000007Dw3sUAC', 'Event_Date__c': '2017-03-08', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2017', 'Status_History__c': 'a132P000000ArG3QAK'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that pembrolizumab be funded for the first-line treatment of patients with previously untreated advanced NSCLC whose tumours express PD-L1 at a level of  Y 50% with a low priority, subject to Special Authority criteria.', 'fs': 'The Subcommittee recommended that pembrolizumab be funded for the first-line treatment of patients with previously untreated advanced NSCLC whose tumours express PD-L1 at a level of  Y 50% with a low priority, subject to Special Authority criteria.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2017-7.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2017-7.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2017', 'fs': 'Mar 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 24 March 2017.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 24 March 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw3tUAC'}, 'Id': 'a0P2P000007Dw3tUAC', 'Event_Date__c': '2017-03-24', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 24 March 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2017-7.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'Low', 'Summary__c': 'The Subcommittee recommended that pembrolizumab be funded for the first-line treatment of patients with previously untreated advanced NSCLC whose tumours express PD-L1 at a level of  Y 50% with a low priority, subject to Special Authority criteria.', 'Formatted_Date__c': 'Mar 2017', 'Status_History__c': 'a132P000000ArGPQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2017', 'fs': 'May 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw3vUAC'}, 'Id': 'a0P2P000007Dw3vUAC', 'Event_Date__c': '2017-05-04', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2017', 'Status_History__c': 'a132P000000ArHNQA0'}, 'change': None}, {'Summary': {'s': 'The Committee deferred making a recommendation regarding the funding of pembrolizumab as a first-line treatment for patients with PD-L1 positive NSCLC pending publication of mature survival data and further information regarding the use of PD-L1 expression as a biomarker.', 'fs': 'The Committee deferred making a recommendation regarding the funding of pembrolizumab as a first-line treatment for patients with PD-L1 positive NSCLC pending publication of mature survival data and further information regarding the use of PD-L1 expression as a biomarker.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2017', 'fs': 'May 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 May 2017.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 May 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw3wUAC'}, 'Id': 'a0P2P000007Dw3wUAC', 'Event_Date__c': '2017-05-04', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 May 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': 'The Committee deferred making a recommendation regarding the funding of pembrolizumab as a first-line treatment for patients with PD-L1 positive NSCLC pending publication of mature survival data and further information regarding the use of PD-L1 expression as a biomarker.', 'Formatted_Date__c': 'May 2017', 'Status_History__c': 'a132P000000ArHPQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2017', 'fs': 'May 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw3xUAC'}, 'Id': 'a0P2P000007Dw3xUAC', 'Event_Date__c': '2017-05-04', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2017', 'Status_History__c': 'a132P000000ArHQQA0'}, 'change': None}, {'Summary': {'s': 'The Committee noted further information from the supplier of pembrolizumab, Merck Sharpe &amp; Dohme, submitted in response to the May 2017 PTAC minutes.', 'fs': 'The Committee noted further information from the supplier of pembrolizumab, Merck Sharpe &amp; Dohme, submitted in response to the May 2017 PTAC minutes.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-11.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-11.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2017', 'fs': 'Nov 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 November 2017.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 November 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw3yUAC'}, 'Id': 'a0P2P000007Dw3yUAC', 'Event_Date__c': '2017-11-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 November 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-11.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Committee noted further information from the supplier of pembrolizumab, Merck Sharpe &amp; Dohme, submitted in response to the May 2017 PTAC minutes.', 'Formatted_Date__c': 'Nov 2017', 'Status_History__c': 'a132P000000ArMaQAK'}, 'change': None}, {'Summary': {'s': 'The Committee noted that the supplier had since further responded to the issues raised by PTAC regarding the funding of pembrolizumab for the treatment of first-line advanced NSCLC.    The Committee considered that the information provided did not address the issues previously raised by PTAC with regards to the application for pembrolizumab as a first-line advanced NSCLC treatment', 'fs': 'The Committee noted that the supplier had since further responded to the issues raised by PTAC regarding the funding of pembrolizumab for the treatment of first-line advanced NSCLC.    The Committee considered that the information provided did not address the issues previously raised by PTAC with regards to the application for pembrolizumab as a first-line advanced NSCLC treatment', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2018', 'fs': 'Aug 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw3zUAC'}, 'Id': 'a0P2P000007Dw3zUAC', 'Event_Date__c': '2018-08-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Committee noted that the supplier had since further responded to the issues raised by PTAC regarding the funding of pembrolizumab for the treatment of first-line advanced NSCLC.    The Committee considered that the information provided did not address the issues previously raised by PTAC with regards to the application for pembrolizumab as a first-line advanced NSCLC treatment', 'Formatted_Date__c': 'Aug 2018', 'Status_History__c': 'a132P000000ArVOQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-11.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-11.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2018', 'fs': 'Nov 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 1 November 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 1 November 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw40UAC'}, 'Id': 'a0P2P000007Dw40UAC', 'Event_Date__c': '2018-11-01', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 1 November 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-11.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Nov 2018', 'Status_History__c': 'a132P000000ArYtQAK'}, 'change': None}, {'Summary': {'s': 'The Committee recommended that pembrolizumab as monotherapy be funded with medium priority for previously untreated advanced PD-L1 positive EGFR wildtype NSCLC noting that uncertainty remained regarding the magnitude of benefit from treatment in this setting and the current high price of pembrolizumab    The Committee recommended that advice be sought from CaTSoP regarding: interpretation of the role of pemetrexed use on the reported survival results in the relevant clinical trials; further information regarding interpretation of the clinical significance of HRQoL and OS data in the context of lung cancer patients; consideration of the relative benefit of monotherapy vs chemotherapy particularly in different patient populations (PD-L1 status, histology or other); and appropriate access criteria for pembrolizumab in the treatment of advanced NSCLC.', 'fs': 'The Committee recommended that pembrolizumab as monotherapy be funded with medium priority for previously untreated advanced PD-L1 positive EGFR wildtype NSCLC noting that uncertainty remained regarding the magnitude of benefit from treatment in this setting and the current high price of pembrolizumab    The Committee recommended that advice be sought from CaTSoP regarding: interpretation of the role of pemetrexed use on the reported survival results in the relevant clinical trials; further information regarding interpretation of the clinical significance of HRQoL and OS data in the context of lung cancer patients; consideration of the relative benefit of monotherapy vs chemotherapy particularly in different patient populations (PD-L1 status, histology or other); and appropriate access criteria for pembrolizumab in the treatment of advanced NSCLC.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2019', 'fs': 'Feb 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw42UAC'}, 'Id': 'a0P2P000007Dw42UAC', 'Event_Date__c': '2019-02-21', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Medium', 'Summary__c': 'The Committee recommended that pembrolizumab as monotherapy be funded with medium priority for previously untreated advanced PD-L1 positive EGFR wildtype NSCLC noting that uncertainty remained regarding the magnitude of benefit from treatment in this setting and the current high price of pembrolizumab    The Committee recommended that advice be sought from CaTSoP regarding: interpretation of the role of pemetrexed use on the reported survival results in the relevant clinical trials; further information regarding interpretation of the clinical significance of HRQoL and OS data in the context of lung cancer patients; consideration of the relative benefit of monotherapy vs chemotherapy particularly in different patient populations (PD-L1 status, histology or other); and appropriate access criteria for pembrolizumab in the treatment of advanced NSCLC.', 'Formatted_Date__c': 'Feb 2019', 'Status_History__c': 'a132P000000ArbxQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2019', 'fs': 'Mar 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw44UAC'}, 'Id': 'a0P2P000007Dw44UAC', 'Event_Date__c': '2019-03-06', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2019', 'Status_History__c': 'a132P000000Ard5QAC'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that pembrolizumab be funded in a first-line setting for advanced NSCLC patients subject to access criteria.', 'fs': 'The Subcommittee recommended that pembrolizumab be funded in a first-line setting for advanced NSCLC patients subject to access criteria.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-04.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-04.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Apr 2019', 'fs': 'Apr 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 April 2019.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 April 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw45UAC'}, 'Id': 'a0P2P000007Dw45UAC', 'Event_Date__c': '2019-04-05', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 April 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-04.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'The Subcommittee recommended that pembrolizumab be funded in a first-line setting for advanced NSCLC patients subject to access criteria.', 'Formatted_Date__c': 'Apr 2019', 'Status_History__c': 'a132P000000AreAQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2020', 'fs': 'Jun 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw46UAC'}, 'Id': 'a0P2P000007Dw46UAC', 'Event_Date__c': '2020-06-15', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2020', 'Status_History__c': 'a132P000000CAqTQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that there were a number of monoclonal antibodies that target PD-1 or PD-L1 inhibitors, previously considered for funding, and in development for use in the treatment of patients with advanced NSCLC either as monotherapy or in combination with other treatments.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that advice was sought by PHARMAC staff regarding the current landscape for ICI agents for NSCLC, including agents currently being considered by PHARMAC and agents that may be considered by PHARMAC in the future.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that it had considered the broader lung cancer treatment paradigm including anti PD-1/anti PD-L1 and targeted agents at its <a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-04.pdf"" target=""_blank"">April 2019</a> meeting.</p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the treatment paradigm for advanced NSCLC continues to evolve due to the number and rate of new lung cancer treatments being developed. However, since the April 2019 meeting, there have been no major new trials published regarding the efficacy of combination anti-CTLA4/anti PD1 agents in the treatment of advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5. </span>The Subcommittee considered that while toxicity related adverse events are less common with anti PD-1/anti PD-L1 agents than with chemotherapy, there was a small portion of patients treated with ICI agents who experience significant immune-mediated adverse events, which require intensive management and monitoring often over a long period of time and often entailed increased clinic visits, treatment with steroids and ongoing immunosuppressants.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that ESMO/ACSO guidelines support use of anti PD-1/anti PD-L1 agents (pembrolizumab, atezolizumab, nivolumab) in the treatment of NSCLC in first and second-line settings, either monotherapy or in combination with chemotherapy and other agents depending on patient and cancer characteristics.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7. </span>The Subcommittee considered that, based on the totality of currently available data, anti PD-1/anti PD-L1 agents appear to provide the same (or similar) effect in the treatment of advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8. </span>The Subcommittee considered that currently pembrolizumab and atezolizumab have the strongest data for use in the first-line setting for advanced NSCLC; and that data is comparable for atezolizumab, pembrolizumab and nivolumab in the second-line. The Subcommittee considered that there is currently a lack of supportive data for avelumab in advanced NSCLC in any setting and for nivolumab in the first-line setting.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted a meta-analysis comparing trials of anti PD-1/anti PD-</p><p style=""text-align: justify;"">L1 agents as monotherapy or in combination with chemotherapy across NSCLC histologies and biomarker expression (<a href=""https://pubmed.ncbi.nlm.nih.gov/31870882/"" target=""_blank"">Lantuejoul et al. J Thorac Oncol. 2020; 15:499-519</a>). The Subcommittee considered that the studies presented heavily overlapped in patient characteristics and outcomes, indicating a similar level of benefit across the various trial agents and populations. It was also considered that diagnostic thresholds for PD-L1 expression were broadly consistent with 50% and 1% thresholds.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted a review of first-line anti PD-1/anti PD-L1 agent trials for NSCLC, in which approximately half of the studies reviewed had hazard ratios for overall survival whose confidence intervals crossed 1, indicating no statistically significant improvements with anti PD-1/anti PD-L1 treatment (<a href=""https://pubmed.ncbi.nlm.nih.gov/32179179/"" target=""_blank"">Remon et al. J Thorac Oncol. 2020;15:914-47</a>).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.11. </span>The Subcommittee reiterated that based on the currently available evidence (across multiple trials and agents) the overall survival gain for NSCLC patients with anti PD-1/anti PD-L1 agents was approximately 3 months irrespective of treatment line. The Subcommittee considered that to date it remained the case that published evidence for the use of anti PD-1/anti PD-L1 agents does not indicate there is a ‘tail’ of long-term survivors with advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.12. </span>The Subcommittee considered a letter regarding the funding of lung cancer treatments in New Zealand from the New Zealand Lung Oncology Special Interest Group (comprising medical oncologists who specialise in the treatment of lung cancer). The Subcommittee noted that, while not unanimous, based on the currently available evidence for use of various agents there was majority support for a class effect for monoclonal antibodies targeting PD-1/PD-L1 in treatment for advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that while there is variability between trials for anti PD-1/anti PD-L1 agents (atezolizumab, pembrolizumab, durvalumab, nivolumab) in how they stratify by PD-L1 expression, participants are generally grouped based on PD-L1 tumour expression of ≥ 50% (high expression), PD-L1 tumour expression of ≥ 1% (PD-L1 positive), and PD-L1 expression &lt;1% (PD-L1 negative).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that although stratification of patients in clinical trials based on PD-L1 expression is relatively consistent across studies, at the current time it is difficult to determine what the downstream immune effects of PD-L1 blockade are and so PD-L1 expression may not be biologically meaningful in defining a patient population for exclusion of benefit of anti PD-1/anti PD-L1 treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.15. </span>The Subcommittee considered that published data indicates that a higher expression of PD-L1 on tumour cells or surrounding immune stromal cells correlates to a higher response rate from ICI agents.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that although patients with high PD-L1 expression appear to benefit most, those with lower expression may also benefit, with a statistically significant and clinically meaningful improvement in overall survival.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that use of different assays, tumour proportion scores, and PD-L1 expression thresholds may lead to problems with reproducibility and standardisation of testing and by extrapolation the benefits observed in trial populations.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that lab-developed tests used in New Zealand may not have the same sensitivity as the tests used in the clinical trials. As a variety of PD-L1 testing platforms are in use in New Zealand, the Subcommittee considered that the true rates of PD-L1 expression in NSCLC for patients in New Zealand may be difficult to estimate.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the majority of research regarding the use of immunotherapies for lung cancer to date has been conducted in patients who do not express targetable driver mutations (e.g. EGFR-negative, ALK-negative). Therefore, the Subcommittee considered there continued to be a lack of data to support efficacy of anti PD-1/anti PD-L1 agents in patients with known driver mutations, such that inclusion of these populations in any funding criteria for anti PD-1/anti PD-L1 agents could not currently be supported.\xa0</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.20. </span>The Subcommittee considered that similarly patients with uncontrolled brain metastases were not included in trial populations, and that in NSCLC this is considered an unfavourable prognostic factor such that it would be appropriate to exclude these patients from funding of these agents.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.21. </span>The Subcommittee considered it remained appropriate to limit patients to a single line of treatment with anti PD-1/anti PD-L1 agents which could be administered at any point in the treatment sequence for patients with EGFR wild-type or ALK-negative advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.22. </span>The Subcommittee considered that it would be appropriate to limit the total duration for a course of anti PD-1/anti PD-L1 treatment for advanced NSCLC patients to a maximum of two years of continuous treatment. The Subcommittee considered that while it was expected there may be gaps in treatment due to adverse events, as with many oncology treatments, there was a lack of data to support retreatment following disease progression in anti PD-1/anti PD-L1 pre-treated NSCLC patients, and that treatment should cease at signs of disease progression (whether this occurred during continuous treatment or in a period when ‘off’ treatment).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, while funding for all advanced NSCLC would be the preferred outcome, if targeting was required for fiscal reasons then use of PD-L1 expression would be reasonable.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.24. </span>The Subcommittee considered there were benefits and shortfalls of a Special Authority criteria mandating PD-L1 testing to determine eligibility for anti PD-1/anti PD-L1 agents for advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.25. </span>The Subcommittee considered that, if anti PD-1/anti PD-L1 agents were to be funded in New Zealand, subject to criteria irrespective of PD-L1 expression (i.e. where PD-L1 level did not determine eligibility for funding) that this would allow clinicians to prescribe anti PD-1/anti PD-L1 agents according to patient needs and clinical judgement. The Subcommittee considered that in this situation it was likely that the majority of patients would receive treatment as a combination regimen with chemotherapy, and only those considered unfit for chemotherapy would likely receive monotherapy.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, conversely, if anti PD-1/anti PD-L1 agents were to be funded in New Zealand subject to criteria that mandated PD-L1 expression (i.e. where PD-L1 level was a required determinant of eligibility for funding) use of a 50% threshold would likely be appropriate. The Subcommittee considered that this could target funded treatment to those that may benefit most and limit the overall resource impact for DHBs.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that if first-line treatment were to be funded for all advanced NSCLC patients (rather than only a high PD-L1 expression population), PD-L1 level would likely be used to determine treatment regimen. The Subcommittee considered that any patients whose disease had high PD-L1 expression (50% or greater) would likely receive anti PD-1/anti PD-L1 monotherapy, with patients whose disease had PD-L1 expression less than 50% who are ‘fit’ receiving the combination regimen. The Subcommittee considered that in this scenario patients who are ‘unfit’ to receive chemotherapy and did not have disease with high expression of PD-L1 may not be eligible to receive funded anti PD-1/anti PD-L1 treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that mandating PD-L1 testing would require DHBs to fund and provide tests but may create inequities for patients who are unfit for chemotherapy and may not meet the specified PD-L1 expression threshold.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.29. </span>The Subcommittee considered that if PD-L1 testing was not used to specify eligibility for funding, it was uncertain whether testing would be implemented equitably by DHBs. The Subcommittee considered this may result in more patients receiving combination chemotherapy regimens with the additional toxicities and resourcing requirements when comparable benefit could likely be achieved without this.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.30.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, given these points, it would be reasonable to progress funding for anti PD-1/anti PD-L1 agents in the treatment of advanced NSCLC subject to criteria with or without specification of PD-L1 based on assessment of the most favourable cost-effectiveness taking in to account the health system impacts.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.31.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that appropriate criteria in each scenario would be:</p><p style=""text-align: justify;""><u>PD-L1 defined population</u></p><p><br></p><p><span style=""font-size: 9pt;"">Initial application - (NSCLC first-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior treatment with an immune checkpoint inhibitor for non-small cell lung cancer (NSCLC); and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either:</span></p><p><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">2.1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic, unresectable, NSCLC; and</span></p><p><span style=""font-size: 9pt;"">2.1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">The patient has not had prior chemotherapy treatment for their disease; and</span></p><p><span style=""font-size: 9pt;"">2.1.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p><span style=""font-size: 9pt;"">2.1.4.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming the disease expresses PD-L1 at a level of equal or greater than 50% as determined by a validated diagnostic test; and</span></p><p><span style=""font-size: 9pt;"">2.1.5.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p><span style=""font-size: 9pt;"">2.1.6.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p><span style=""font-size: 9pt;"">2.1.7.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">[Chemical] to be used as monotherapy at a maximum dose of [dose] for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">2.1.8.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented; or</span></p><p><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">2.2.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has metastatic, unresectable, NSCLC; and</span></p><p><span style=""font-size: 9pt;"">2.2.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">The patient has not had prior treatment for their metastatic disease; and</span></p><p><span style=""font-size: 9pt;"">2.2.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p><span style=""font-size: 9pt;"">2.2.4.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p><span style=""font-size: 9pt;"">2.2.5.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p><span style=""font-size: 9pt;"">2.2.6.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">[Chemical] to be used in combination with chemotherapy at a maximum dose of [dose] for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">2.2.7.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented.</span></p><p><br></p><p><br></p><p><span style=""font-size: 9pt;"">Initial application- (NSCLC second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic non-small cell lung cancer (NSCLC); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has documented disease progression following treatment with platinum-based chemotherapy; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not had prior treatment with immune checkpoint inhibitors for NSCLC; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[Chemical] is to be used as monotherapy at a dose of [dose] for a maximum of 12 weeks; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">8.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented as per RECIST criteria.</span></p><p><br></p><p><br></p><p><span style=""font-size: 9pt;"">Renewal – (NSCLC first or second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment according to RECIST criteria; or</span></p><p><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment according to RECIST criteria; or</span></p><p><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease according to RECIST criteria; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression according to RECIST criteria; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[chemical] to be used at a maximum dose of [dose] (or equivalent); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[chemical] to be discontinued at signs of disease progression; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment with [chemical] to cease after a total duration of 24 months from commencement.</span></p><p style=""text-align: justify;""><b>\xa0</b></p><p style=""text-align: justify;""><u>Irrespective of PD-L1 (regimen/dose not defined either)</u></p><p style=""text-align: justify;""><b>\xa0</b></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application - (NSCLC first-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior treatment with an immune checkpoint inhibitor for non-small cell lung cancer (NSCLC); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic, unresectable, NSCLC; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has not had prior chemotherapy treatment for their disease; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented.</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application- (NSCLC second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic non-small cell lung cancer (NSCLC); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has documented disease progression following treatment with platinum-based chemotherapy; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not had prior treatment with immune checkpoint inhibitors for NSCLC; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented as per RECIST criteria.</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Renewal – (NSCLC first or second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment according to RECIST criteria; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment according to RECIST criteria; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease according to RECIST criteria; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression according to RECIST criteria; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[Chemical] to be discontinued at signs of disease progression; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Treatment with [chemical] to cease after a total duration of 24 months from commencement.</span></p><p><br></p>', 'fs': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that there were a number of monoclonal antibodies that target PD-1 or PD-L1 inhibitors, previously considered for funding, and in development for use in the treatment of patients with advanced NSCLC either as monotherapy or in combination with other treatments.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that advice was sought by PHARMAC staff regarding the current landscape for ICI agents for NSCLC, including agents currently being considered by PHARMAC and agents that may be considered by PHARMAC in the future.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that it had considered the broader lung cancer treatment paradigm including anti PD-1/anti PD-L1 and targeted agents at its <a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-04.pdf"" target=""_blank"">April 2019</a> meeting.</p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the treatment paradigm for advanced NSCLC continues to evolve due to the number and rate of new lung cancer treatments being developed. However, since the April 2019 meeting, there have been no major new trials published regarding the efficacy of combination anti-CTLA4/anti PD1 agents in the treatment of advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5. </span>The Subcommittee considered that while toxicity related adverse events are less common with anti PD-1/anti PD-L1 agents than with chemotherapy, there was a small portion of patients treated with ICI agents who experience significant immune-mediated adverse events, which require intensive management and monitoring often over a long period of time and often entailed increased clinic visits, treatment with steroids and ongoing immunosuppressants.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that ESMO/ACSO guidelines support use of anti PD-1/anti PD-L1 agents (pembrolizumab, atezolizumab, nivolumab) in the treatment of NSCLC in first and second-line settings, either monotherapy or in combination with chemotherapy and other agents depending on patient and cancer characteristics.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7. </span>The Subcommittee considered that, based on the totality of currently available data, anti PD-1/anti PD-L1 agents appear to provide the same (or similar) effect in the treatment of advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8. </span>The Subcommittee considered that currently pembrolizumab and atezolizumab have the strongest data for use in the first-line setting for advanced NSCLC; and that data is comparable for atezolizumab, pembrolizumab and nivolumab in the second-line. The Subcommittee considered that there is currently a lack of supportive data for avelumab in advanced NSCLC in any setting and for nivolumab in the first-line setting.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted a meta-analysis comparing trials of anti PD-1/anti PD-</p><p style=""text-align: justify;"">L1 agents as monotherapy or in combination with chemotherapy across NSCLC histologies and biomarker expression (<a href=""https://pubmed.ncbi.nlm.nih.gov/31870882/"" target=""_blank"">Lantuejoul et al. J Thorac Oncol. 2020; 15:499-519</a>). The Subcommittee considered that the studies presented heavily overlapped in patient characteristics and outcomes, indicating a similar level of benefit across the various trial agents and populations. It was also considered that diagnostic thresholds for PD-L1 expression were broadly consistent with 50% and 1% thresholds.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted a review of first-line anti PD-1/anti PD-L1 agent trials for NSCLC, in which approximately half of the studies reviewed had hazard ratios for overall survival whose confidence intervals crossed 1, indicating no statistically significant improvements with anti PD-1/anti PD-L1 treatment (<a href=""https://pubmed.ncbi.nlm.nih.gov/32179179/"" target=""_blank"">Remon et al. J Thorac Oncol. 2020;15:914-47</a>).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.11. </span>The Subcommittee reiterated that based on the currently available evidence (across multiple trials and agents) the overall survival gain for NSCLC patients with anti PD-1/anti PD-L1 agents was approximately 3 months irrespective of treatment line. The Subcommittee considered that to date it remained the case that published evidence for the use of anti PD-1/anti PD-L1 agents does not indicate there is a ‘tail’ of long-term survivors with advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.12. </span>The Subcommittee considered a letter regarding the funding of lung cancer treatments in New Zealand from the New Zealand Lung Oncology Special Interest Group (comprising medical oncologists who specialise in the treatment of lung cancer). The Subcommittee noted that, while not unanimous, based on the currently available evidence for use of various agents there was majority support for a class effect for monoclonal antibodies targeting PD-1/PD-L1 in treatment for advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that while there is variability between trials for anti PD-1/anti PD-L1 agents (atezolizumab, pembrolizumab, durvalumab, nivolumab) in how they stratify by PD-L1 expression, participants are generally grouped based on PD-L1 tumour expression of ≥ 50% (high expression), PD-L1 tumour expression of ≥ 1% (PD-L1 positive), and PD-L1 expression &lt;1% (PD-L1 negative).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that although stratification of patients in clinical trials based on PD-L1 expression is relatively consistent across studies, at the current time it is difficult to determine what the downstream immune effects of PD-L1 blockade are and so PD-L1 expression may not be biologically meaningful in defining a patient population for exclusion of benefit of anti PD-1/anti PD-L1 treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.15. </span>The Subcommittee considered that published data indicates that a higher expression of PD-L1 on tumour cells or surrounding immune stromal cells correlates to a higher response rate from ICI agents.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that although patients with high PD-L1 expression appear to benefit most, those with lower expression may also benefit, with a statistically significant and clinically meaningful improvement in overall survival.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that use of different assays, tumour proportion scores, and PD-L1 expression thresholds may lead to problems with reproducibility and standardisation of testing and by extrapolation the benefits observed in trial populations.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that lab-developed tests used in New Zealand may not have the same sensitivity as the tests used in the clinical trials. As a variety of PD-L1 testing platforms are in use in New Zealand, the Subcommittee considered that the true rates of PD-L1 expression in NSCLC for patients in New Zealand may be difficult to estimate.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the majority of research regarding the use of immunotherapies for lung cancer to date has been conducted in patients who do not express targetable driver mutations (e.g. EGFR-negative, ALK-negative). Therefore, the Subcommittee considered there continued to be a lack of data to support efficacy of anti PD-1/anti PD-L1 agents in patients with known driver mutations, such that inclusion of these populations in any funding criteria for anti PD-1/anti PD-L1 agents could not currently be supported.\xa0</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.20. </span>The Subcommittee considered that similarly patients with uncontrolled brain metastases were not included in trial populations, and that in NSCLC this is considered an unfavourable prognostic factor such that it would be appropriate to exclude these patients from funding of these agents.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.21. </span>The Subcommittee considered it remained appropriate to limit patients to a single line of treatment with anti PD-1/anti PD-L1 agents which could be administered at any point in the treatment sequence for patients with EGFR wild-type or ALK-negative advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.22. </span>The Subcommittee considered that it would be appropriate to limit the total duration for a course of anti PD-1/anti PD-L1 treatment for advanced NSCLC patients to a maximum of two years of continuous treatment. The Subcommittee considered that while it was expected there may be gaps in treatment due to adverse events, as with many oncology treatments, there was a lack of data to support retreatment following disease progression in anti PD-1/anti PD-L1 pre-treated NSCLC patients, and that treatment should cease at signs of disease progression (whether this occurred during continuous treatment or in a period when ‘off’ treatment).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, while funding for all advanced NSCLC would be the preferred outcome, if targeting was required for fiscal reasons then use of PD-L1 expression would be reasonable.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.24. </span>The Subcommittee considered there were benefits and shortfalls of a Special Authority criteria mandating PD-L1 testing to determine eligibility for anti PD-1/anti PD-L1 agents for advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.25. </span>The Subcommittee considered that, if anti PD-1/anti PD-L1 agents were to be funded in New Zealand, subject to criteria irrespective of PD-L1 expression (i.e. where PD-L1 level did not determine eligibility for funding) that this would allow clinicians to prescribe anti PD-1/anti PD-L1 agents according to patient needs and clinical judgement. The Subcommittee considered that in this situation it was likely that the majority of patients would receive treatment as a combination regimen with chemotherapy, and only those considered unfit for chemotherapy would likely receive monotherapy.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, conversely, if anti PD-1/anti PD-L1 agents were to be funded in New Zealand subject to criteria that mandated PD-L1 expression (i.e. where PD-L1 level was a required determinant of eligibility for funding) use of a 50% threshold would likely be appropriate. The Subcommittee considered that this could target funded treatment to those that may benefit most and limit the overall resource impact for DHBs.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that if first-line treatment were to be funded for all advanced NSCLC patients (rather than only a high PD-L1 expression population), PD-L1 level would likely be used to determine treatment regimen. The Subcommittee considered that any patients whose disease had high PD-L1 expression (50% or greater) would likely receive anti PD-1/anti PD-L1 monotherapy, with patients whose disease had PD-L1 expression less than 50% who are ‘fit’ receiving the combination regimen. The Subcommittee considered that in this scenario patients who are ‘unfit’ to receive chemotherapy and did not have disease with high expression of PD-L1 may not be eligible to receive funded anti PD-1/anti PD-L1 treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that mandating PD-L1 testing would require DHBs to fund and provide tests but may create inequities for patients who are unfit for chemotherapy and may not meet the specified PD-L1 expression threshold.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.29. </span>The Subcommittee considered that if PD-L1 testing was not used to specify eligibility for funding, it was uncertain whether testing would be implemented equitably by DHBs. The Subcommittee considered this may result in more patients receiving combination chemotherapy regimens with the additional toxicities and resourcing requirements when comparable benefit could likely be achieved without this.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.30.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, given these points, it would be reasonable to progress funding for anti PD-1/anti PD-L1 agents in the treatment of advanced NSCLC subject to criteria with or without specification of PD-L1 based on assessment of the most favourable cost-effectiveness taking in to account the health system impacts.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.31.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that appropriate criteria in each scenario would be:</p><p style=""text-align: justify;""><u>PD-L1 defined population</u></p><p><br></p><p><span style=""font-size: 9pt;"">Initial application - (NSCLC first-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior treatment with an immune checkpoint inhibitor for non-small cell lung cancer (NSCLC); and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either:</span></p><p><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">2.1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic, unresectable, NSCLC; and</span></p><p><span style=""font-size: 9pt;"">2.1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">The patient has not had prior chemotherapy treatment for their disease; and</span></p><p><span style=""font-size: 9pt;"">2.1.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p><span style=""font-size: 9pt;"">2.1.4.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming the disease expresses PD-L1 at a level of equal or greater than 50% as determined by a validated diagnostic test; and</span></p><p><span style=""font-size: 9pt;"">2.1.5.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p><span style=""font-size: 9pt;"">2.1.6.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p><span style=""font-size: 9pt;"">2.1.7.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">[Chemical] to be used as monotherapy at a maximum dose of [dose] for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">2.1.8.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented; or</span></p><p><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">2.2.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has metastatic, unresectable, NSCLC; and</span></p><p><span style=""font-size: 9pt;"">2.2.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">The patient has not had prior treatment for their metastatic disease; and</span></p><p><span style=""font-size: 9pt;"">2.2.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p><span style=""font-size: 9pt;"">2.2.4.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p><span style=""font-size: 9pt;"">2.2.5.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p><span style=""font-size: 9pt;"">2.2.6.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">[Chemical] to be used in combination with chemotherapy at a maximum dose of [dose] for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">2.2.7.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented.</span></p><p><br></p><p><br></p><p><span style=""font-size: 9pt;"">Initial application- (NSCLC second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic non-small cell lung cancer (NSCLC); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has documented disease progression following treatment with platinum-based chemotherapy; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not had prior treatment with immune checkpoint inhibitors for NSCLC; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[Chemical] is to be used as monotherapy at a dose of [dose] for a maximum of 12 weeks; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">8.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented as per RECIST criteria.</span></p><p><br></p><p><br></p><p><span style=""font-size: 9pt;"">Renewal – (NSCLC first or second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment according to RECIST criteria; or</span></p><p><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment according to RECIST criteria; or</span></p><p><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease according to RECIST criteria; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression according to RECIST criteria; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[chemical] to be used at a maximum dose of [dose] (or equivalent); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[chemical] to be discontinued at signs of disease progression; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment with [chemical] to cease after a total duration of 24 months from commencement.</span></p><p style=""text-align: justify;""><b>\xa0</b></p><p style=""text-align: justify;""><u>Irrespective of PD-L1 (regimen/dose not defined either)</u></p><p style=""text-align: justify;""><b>\xa0</b></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application - (NSCLC first-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior treatment with an immune checkpoint inhibitor for non-small cell lung cancer (NSCLC); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic, unresectable, NSCLC; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has not had prior chemotherapy treatment for their disease; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented.</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application- (NSCLC second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic non-small cell lung cancer (NSCLC); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has documented disease progression following treatment with platinum-based chemotherapy; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not had prior treatment with immune checkpoint inhibitors for NSCLC; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented as per RECIST criteria.</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Renewal – (NSCLC first or second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment according to RECIST criteria; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment according to RECIST criteria; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease according to RECIST criteria; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression according to RECIST criteria; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[Chemical] to be discontinued at signs of disease progression; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Treatment with [chemical] to cease after a total duration of 24 months from commencement.</span></p><p><br></p>', 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': '<p>At its August 2020 meeting: </p><p><br></p><p>The Committee noted that CaTSoP considered it would be appropriate to determine whether to define a population eligible for funded access, by mandating PD-L1 testing or not in any access criteria, based on economic assessment of the most favourable cost-effectiveness taking into account the costs to the health system and implementation issues associated with PD-L1 testing as discussed in CaTSoP’s July 2020 record and previous PTAC and CaTSoP records related to PD1/PD-L1 inhibitors.</p><p><br></p><p>The Committee considered that it was not clear from the drafting of the CaTSoP record that the Subcommittee’s consideration of a difference in estimated median survival of three months (compared with comparator treatment) for NSCLC patients with antiPD1/PD-L1 agents irrespective of treatment line was in reference to an ‘all comer’ population (regardless of histology and biomarker status). The Committee considered that a high PDL1 expression subpopulation would have a larger gain than this.</p>', 'fs': '<p>At its August 2020 meeting: </p><p><br></p><p>The Committee noted that CaTSoP considered it would be appropriate to determine whether to define a population eligible for funded access, by mandating PD-L1 testing or not in any access criteria, based on economic assessment of the most favourable cost-effectiveness taking into account the costs to the health system and implementation issues associated with PD-L1 testing as discussed in CaTSoP’s July 2020 record and previous PTAC and CaTSoP records related to PD1/PD-L1 inhibitors.</p><p><br></p><p>The Committee considered that it was not clear from the drafting of the CaTSoP record that the Subcommittee’s consideration of a difference in estimated median survival of three months (compared with comparator treatment) for NSCLC patients with antiPD1/PD-L1 agents irrespective of treatment line was in reference to an ‘all comer’ population (regardless of histology and biomarker status). The Committee considered that a high PDL1 expression subpopulation would have a larger gain than this.</p>', 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw47UAC'}, 'Id': 'a0P2P000007Dw47UAC', 'Event_Date__c': '2020-09-29', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2020', 'Published_Discussion__c': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that there were a number of monoclonal antibodies that target PD-1 or PD-L1 inhibitors, previously considered for funding, and in development for use in the treatment of patients with advanced NSCLC either as monotherapy or in combination with other treatments.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that advice was sought by PHARMAC staff regarding the current landscape for ICI agents for NSCLC, including agents currently being considered by PHARMAC and agents that may be considered by PHARMAC in the future.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that it had considered the broader lung cancer treatment paradigm including anti PD-1/anti PD-L1 and targeted agents at its <a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-04.pdf"" target=""_blank"">April 2019</a> meeting.</p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the treatment paradigm for advanced NSCLC continues to evolve due to the number and rate of new lung cancer treatments being developed. However, since the April 2019 meeting, there have been no major new trials published regarding the efficacy of combination anti-CTLA4/anti PD1 agents in the treatment of advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5. </span>The Subcommittee considered that while toxicity related adverse events are less common with anti PD-1/anti PD-L1 agents than with chemotherapy, there was a small portion of patients treated with ICI agents who experience significant immune-mediated adverse events, which require intensive management and monitoring often over a long period of time and often entailed increased clinic visits, treatment with steroids and ongoing immunosuppressants.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that ESMO/ACSO guidelines support use of anti PD-1/anti PD-L1 agents (pembrolizumab, atezolizumab, nivolumab) in the treatment of NSCLC in first and second-line settings, either monotherapy or in combination with chemotherapy and other agents depending on patient and cancer characteristics.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7. </span>The Subcommittee considered that, based on the totality of currently available data, anti PD-1/anti PD-L1 agents appear to provide the same (or similar) effect in the treatment of advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8. </span>The Subcommittee considered that currently pembrolizumab and atezolizumab have the strongest data for use in the first-line setting for advanced NSCLC; and that data is comparable for atezolizumab, pembrolizumab and nivolumab in the second-line. The Subcommittee considered that there is currently a lack of supportive data for avelumab in advanced NSCLC in any setting and for nivolumab in the first-line setting.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee noted a meta-analysis comparing trials of anti PD-1/anti PD-</p><p style=""text-align: justify;"">L1 agents as monotherapy or in combination with chemotherapy across NSCLC histologies and biomarker expression (<a href=""https://pubmed.ncbi.nlm.nih.gov/31870882/"" target=""_blank"">Lantuejoul et al. J Thorac Oncol. 2020; 15:499-519</a>). The Subcommittee considered that the studies presented heavily overlapped in patient characteristics and outcomes, indicating a similar level of benefit across the various trial agents and populations. It was also considered that diagnostic thresholds for PD-L1 expression were broadly consistent with 50% and 1% thresholds.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted a review of first-line anti PD-1/anti PD-L1 agent trials for NSCLC, in which approximately half of the studies reviewed had hazard ratios for overall survival whose confidence intervals crossed 1, indicating no statistically significant improvements with anti PD-1/anti PD-L1 treatment (<a href=""https://pubmed.ncbi.nlm.nih.gov/32179179/"" target=""_blank"">Remon et al. J Thorac Oncol. 2020;15:914-47</a>).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.11. </span>The Subcommittee reiterated that based on the currently available evidence (across multiple trials and agents) the overall survival gain for NSCLC patients with anti PD-1/anti PD-L1 agents was approximately 3 months irrespective of treatment line. The Subcommittee considered that to date it remained the case that published evidence for the use of anti PD-1/anti PD-L1 agents does not indicate there is a ‘tail’ of long-term survivors with advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.12. </span>The Subcommittee considered a letter regarding the funding of lung cancer treatments in New Zealand from the New Zealand Lung Oncology Special Interest Group (comprising medical oncologists who specialise in the treatment of lung cancer). The Subcommittee noted that, while not unanimous, based on the currently available evidence for use of various agents there was majority support for a class effect for monoclonal antibodies targeting PD-1/PD-L1 in treatment for advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that while there is variability between trials for anti PD-1/anti PD-L1 agents (atezolizumab, pembrolizumab, durvalumab, nivolumab) in how they stratify by PD-L1 expression, participants are generally grouped based on PD-L1 tumour expression of ≥ 50% (high expression), PD-L1 tumour expression of ≥ 1% (PD-L1 positive), and PD-L1 expression &lt;1% (PD-L1 negative).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that although stratification of patients in clinical trials based on PD-L1 expression is relatively consistent across studies, at the current time it is difficult to determine what the downstream immune effects of PD-L1 blockade are and so PD-L1 expression may not be biologically meaningful in defining a patient population for exclusion of benefit of anti PD-1/anti PD-L1 treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.15. </span>The Subcommittee considered that published data indicates that a higher expression of PD-L1 on tumour cells or surrounding immune stromal cells correlates to a higher response rate from ICI agents.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that although patients with high PD-L1 expression appear to benefit most, those with lower expression may also benefit, with a statistically significant and clinically meaningful improvement in overall survival.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that use of different assays, tumour proportion scores, and PD-L1 expression thresholds may lead to problems with reproducibility and standardisation of testing and by extrapolation the benefits observed in trial populations.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that lab-developed tests used in New Zealand may not have the same sensitivity as the tests used in the clinical trials. As a variety of PD-L1 testing platforms are in use in New Zealand, the Subcommittee considered that the true rates of PD-L1 expression in NSCLC for patients in New Zealand may be difficult to estimate.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that the majority of research regarding the use of immunotherapies for lung cancer to date has been conducted in patients who do not express targetable driver mutations (e.g. EGFR-negative, ALK-negative). Therefore, the Subcommittee considered there continued to be a lack of data to support efficacy of anti PD-1/anti PD-L1 agents in patients with known driver mutations, such that inclusion of these populations in any funding criteria for anti PD-1/anti PD-L1 agents could not currently be supported.\xa0</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.20. </span>The Subcommittee considered that similarly patients with uncontrolled brain metastases were not included in trial populations, and that in NSCLC this is considered an unfavourable prognostic factor such that it would be appropriate to exclude these patients from funding of these agents.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.21. </span>The Subcommittee considered it remained appropriate to limit patients to a single line of treatment with anti PD-1/anti PD-L1 agents which could be administered at any point in the treatment sequence for patients with EGFR wild-type or ALK-negative advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.22. </span>The Subcommittee considered that it would be appropriate to limit the total duration for a course of anti PD-1/anti PD-L1 treatment for advanced NSCLC patients to a maximum of two years of continuous treatment. The Subcommittee considered that while it was expected there may be gaps in treatment due to adverse events, as with many oncology treatments, there was a lack of data to support retreatment following disease progression in anti PD-1/anti PD-L1 pre-treated NSCLC patients, and that treatment should cease at signs of disease progression (whether this occurred during continuous treatment or in a period when ‘off’ treatment).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, while funding for all advanced NSCLC would be the preferred outcome, if targeting was required for fiscal reasons then use of PD-L1 expression would be reasonable.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.24. </span>The Subcommittee considered there were benefits and shortfalls of a Special Authority criteria mandating PD-L1 testing to determine eligibility for anti PD-1/anti PD-L1 agents for advanced NSCLC.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.25. </span>The Subcommittee considered that, if anti PD-1/anti PD-L1 agents were to be funded in New Zealand, subject to criteria irrespective of PD-L1 expression (i.e. where PD-L1 level did not determine eligibility for funding) that this would allow clinicians to prescribe anti PD-1/anti PD-L1 agents according to patient needs and clinical judgement. The Subcommittee considered that in this situation it was likely that the majority of patients would receive treatment as a combination regimen with chemotherapy, and only those considered unfit for chemotherapy would likely receive monotherapy.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, conversely, if anti PD-1/anti PD-L1 agents were to be funded in New Zealand subject to criteria that mandated PD-L1 expression (i.e. where PD-L1 level was a required determinant of eligibility for funding) use of a 50% threshold would likely be appropriate. The Subcommittee considered that this could target funded treatment to those that may benefit most and limit the overall resource impact for DHBs.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.27.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that if first-line treatment were to be funded for all advanced NSCLC patients (rather than only a high PD-L1 expression population), PD-L1 level would likely be used to determine treatment regimen. The Subcommittee considered that any patients whose disease had high PD-L1 expression (50% or greater) would likely receive anti PD-1/anti PD-L1 monotherapy, with patients whose disease had PD-L1 expression less than 50% who are ‘fit’ receiving the combination regimen. The Subcommittee considered that in this scenario patients who are ‘unfit’ to receive chemotherapy and did not have disease with high expression of PD-L1 may not be eligible to receive funded anti PD-1/anti PD-L1 treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.28.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span>The Subcommittee considered that mandating PD-L1 testing would require DHBs to fund and provide tests but may create inequities for patients who are unfit for chemotherapy and may not meet the specified PD-L1 expression threshold.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.29. </span>The Subcommittee considered that if PD-L1 testing was not used to specify eligibility for funding, it was uncertain whether testing would be implemented equitably by DHBs. The Subcommittee considered this may result in more patients receiving combination chemotherapy regimens with the additional toxicities and resourcing requirements when comparable benefit could likely be achieved without this.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.30.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that, given these points, it would be reasonable to progress funding for anti PD-1/anti PD-L1 agents in the treatment of advanced NSCLC subject to criteria with or without specification of PD-L1 based on assessment of the most favourable cost-effectiveness taking in to account the health system impacts.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.31.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee considered that appropriate criteria in each scenario would be:</p><p style=""text-align: justify;""><u>PD-L1 defined population</u></p><p><br></p><p><span style=""font-size: 9pt;"">Initial application - (NSCLC first-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior treatment with an immune checkpoint inhibitor for non-small cell lung cancer (NSCLC); and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either:</span></p><p><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">2.1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic, unresectable, NSCLC; and</span></p><p><span style=""font-size: 9pt;"">2.1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">The patient has not had prior chemotherapy treatment for their disease; and</span></p><p><span style=""font-size: 9pt;"">2.1.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p><span style=""font-size: 9pt;"">2.1.4.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming the disease expresses PD-L1 at a level of equal or greater than 50% as determined by a validated diagnostic test; and</span></p><p><span style=""font-size: 9pt;"">2.1.5.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p><span style=""font-size: 9pt;"">2.1.6.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p><span style=""font-size: 9pt;"">2.1.7.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">[Chemical] to be used as monotherapy at a maximum dose of [dose] for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">2.1.8.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented; or</span></p><p><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">2.2.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has metastatic, unresectable, NSCLC; and</span></p><p><span style=""font-size: 9pt;"">2.2.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">The patient has not had prior treatment for their metastatic disease; and</span></p><p><span style=""font-size: 9pt;"">2.2.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p><span style=""font-size: 9pt;"">2.2.4.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p><span style=""font-size: 9pt;"">2.2.5.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p><span style=""font-size: 9pt;"">2.2.6.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">[Chemical] to be used in combination with chemotherapy at a maximum dose of [dose] for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">2.2.7.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented.</span></p><p><br></p><p><br></p><p><span style=""font-size: 9pt;"">Initial application- (NSCLC second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic non-small cell lung cancer (NSCLC); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has documented disease progression following treatment with platinum-based chemotherapy; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not had prior treatment with immune checkpoint inhibitors for NSCLC; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[Chemical] is to be used as monotherapy at a dose of [dose] for a maximum of 12 weeks; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">8.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented as per RECIST criteria.</span></p><p><br></p><p><br></p><p><span style=""font-size: 9pt;"">Renewal – (NSCLC first or second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment according to RECIST criteria; or</span></p><p><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment according to RECIST criteria; or</span></p><p><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease according to RECIST criteria; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression according to RECIST criteria; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[chemical] to be used at a maximum dose of [dose] (or equivalent); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[chemical] to be discontinued at signs of disease progression; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment with [chemical] to cease after a total duration of 24 months from commencement.</span></p><p style=""text-align: justify;""><b>\xa0</b></p><p style=""text-align: justify;""><u>Irrespective of PD-L1 (regimen/dose not defined either)</u></p><p style=""text-align: justify;""><b>\xa0</b></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application - (NSCLC first-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior treatment with an immune checkpoint inhibitor for non-small cell lung cancer (NSCLC); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic, unresectable, NSCLC; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has not had prior chemotherapy treatment for their disease; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented.</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application- (NSCLC second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic non-small cell lung cancer (NSCLC); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express driver mutations of EGFR or ALK tyrosine kinase; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-1; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient does not have uncontrolled brain metastases; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has documented disease progression following treatment with platinum-based chemotherapy; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not had prior treatment with immune checkpoint inhibitors for NSCLC; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented as per RECIST criteria.</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Renewal – (NSCLC first or second-line) only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment according to RECIST criteria; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment according to RECIST criteria; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease according to RECIST criteria; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression according to RECIST criteria; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">[Chemical] to be discontinued at signs of disease progression; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Treatment with [chemical] to cease after a total duration of 24 months from commencement.</span></p><p><br></p>', 'PTAC_Comments__c': '<p>At its August 2020 meeting: </p><p><br></p><p>The Committee noted that CaTSoP considered it would be appropriate to determine whether to define a population eligible for funded access, by mandating PD-L1 testing or not in any access criteria, based on economic assessment of the most favourable cost-effectiveness taking into account the costs to the health system and implementation issues associated with PD-L1 testing as discussed in CaTSoP’s July 2020 record and previous PTAC and CaTSoP records related to PD1/PD-L1 inhibitors.</p><p><br></p><p>The Committee considered that it was not clear from the drafting of the CaTSoP record that the Subcommittee’s consideration of a difference in estimated median survival of three months (compared with comparator treatment) for NSCLC patients with antiPD1/PD-L1 agents irrespective of treatment line was in reference to an ‘all comer’ population (regardless of histology and biomarker status). The Committee considered that a high PDL1 expression subpopulation would have a larger gain than this.</p>', 'Status_History__c': 'a132P000000CDC5QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw48UAC'}, 'Id': 'a0P2P000007Dw48UAC', 'Event_Date__c': '2022-03-25', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000DdZvQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">2022-04-08-Cancer-Treatments-AC-Record.pdf (pharmac.govt.nz)</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">2022-04-08-Cancer-Treatments-AC-Record.pdf (pharmac.govt.nz)</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2022', 'fs': 'Aug 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 8 April 2022.', 'fs': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 8 April 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw49UAC'}, 'Id': 'a0P2P000007Dw49UAC', 'Event_Date__c': '2022-08-05', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 8 April 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">2022-04-08-Cancer-Treatments-AC-Record.pdf (pharmac.govt.nz)</a></p>', 'Formatted_Date__c': 'Aug 2022', 'Status_History__c': 'a132P000000DxqwQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw4AUAS'}, 'Id': 'a0P2P000007Dw4AUAS', 'Event_Date__c': '2022-10-03', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2022', 'Status_History__c': 'a132P000000EDOeQAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 14 October 2022', 'fs': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 14 October 2022', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw4BUAS'}, 'Id': 'a0P2P000007Dw4BUAS', 'Event_Date__c': '2022-10-07', 'Event_Description__c': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 14 October 2022', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2022', 'Status_History__c': 'a132P000000EDP4QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that either atezolizumab or pembrolizumab should be funded as monotherapy for the first line treatment of advanced non-small cell lung cancer (NSCLC) subject to the following Special Authority criteria:</p><p><strong style=""font-size: 9pt;"">Initial application - (non-small cell lung cancer first-line monotherapy)</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has not had chemotherapy for their disease in the palliative setting; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both </span></p><p><span style=""font-size: 9pt;"">5.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be used as monotherapy; and</span></p><p><span style=""font-size: 9pt;"">5.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming the disease expresses PD-L1 at a level ≥50% as determined by a validated test unless not possible to ascertain; and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-2; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be used at a maximum dose of XXXX every XXX weeks (or equivalent) for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">8.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented clinically and radiologically.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">Renewal – (non-small cell lung cancer first line monotherapy)</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be used at a maximum dose of XXXX every XXXX weeks (or equivalent); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be discontinued at signs of disease progression; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment with XXXXX to cease after a total duration of 24 months from commencement (or equivalent).</span></p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that either atezolizumab or pembrolizumab should be funded as monotherapy for the first line treatment of advanced non-small cell lung cancer (NSCLC) subject to the following Special Authority criteria:</p><p><strong style=""font-size: 9pt;"">Initial application - (non-small cell lung cancer first-line monotherapy)</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has not had chemotherapy for their disease in the palliative setting; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both </span></p><p><span style=""font-size: 9pt;"">5.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be used as monotherapy; and</span></p><p><span style=""font-size: 9pt;"">5.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming the disease expresses PD-L1 at a level ≥50% as determined by a validated test unless not possible to ascertain; and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-2; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be used at a maximum dose of XXXX every XXX weeks (or equivalent) for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">8.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented clinically and radiologically.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">Renewal – (non-small cell lung cancer first line monotherapy)</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be used at a maximum dose of XXXX every XXXX weeks (or equivalent); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be discontinued at signs of disease progression; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment with XXXXX to cease after a total duration of 24 months from commencement (or equivalent).</span></p>', 'change': None}, 'Published_Discussion': {'s': '<h3><em>Background</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009rmyy/p001521"" target=""_blank"">atezolizumab</a> and <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pu56/p000583"" target=""_blank"">pembrolizumab</a> have been previously considered as first line monotherapy treatment for NSCLC, and that both have previously received high funding recommendations from the Cancer Treatments Advisory Committee (CTAC).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">April 2022</a>, CTAC provided advice to Pharmac regarding commercial options for stage IV lung cancer treatments. The Committee noted at the April 2022 meeting, the available evidence and that it remained appropriate to consider that atezolizumab and pembrolizumab provide the same, or similar, health benefit for first line NSCLC monotherapy, such that funding of either agent in this line of therapy would be clinically appropriate. The Committee also considered at the April 2022 meeting that it was appropriate to assess previously assessed ICI agents as having a class effect for the purpose of enabling listing.</p><h3><br></h3><h3><em>Pembrolizumab and atezolizumab monotherapy</em></h3><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted additional follow-up data for pembrolizumab first-line monotherapy (<a href=""https://pubmed.ncbi.nlm.nih.gov/33872070/"" target=""_blank"">Reck et al. J Clin Oncol. 2021;39:2339-49</a>; <a href=""https://jitc.bmj.com/content/9/Suppl_2/A390"" target=""_blank"">de Castro et al. J Immunother Cancer. 2021; 0.1136/jitc-2021-SITC2021.363</a>), and atezolizumab first line monotherapy (<a href=""https://pubmed.ncbi.nlm.nih.gov/34265434/"" target=""_blank"">Jassem et al. J Thorac Oncol. 2021;16:1872-82</a>). The data reviewed for both included three-year follow-up data for atezolizumab and five-year follow-up data for pembrolizumab.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Phase III randomised controlled trials often assume a baseline hazard ratio (HR), and that the proportional change in hazard stays the same over time, so that theoretically the hazard ratios are the same at all time points which does not account for a time-treatment interaction. The Committee noted that deviations from proportional hazards are common for immunotherapy trials (57% of 263 trials studied), with hazard ratios dropping over time (<a href=""https://pubmed.ncbi.nlm.nih.gov/31345838/"" target=""_blank"">Rahman et al. Clin Cancer Res. 2019;25:6339-45</a>). The Committee noted that the changes in HR over time with immunotherapies is further confounded by cross-over within the trial and subsequent therapies.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the longer-term data from KEYNOTE-024 shows a smaller percentage benefit than the proportional hazard ratio would imply, but that there may be a small, yet undefined subpopulation with a longer-term benefit. The Committee also noted that earlier exposure to immunotherapy shows a greater benefit than those who received chemotherapy and then crossed over to pembrolizumab (ie the hazard ratio advantage for immunotherapy increases with time).</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the longer-term follow-up data for atezolizumab in Impower110 reported around 20% of patients experienced long term survival and considered this similar to the long-term results reported for pembrolizumab.</p><h3><br></h3><h3><em>Selectivity and specificity of PD-L1 antibodies</em></h3><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that immunohistochemical analysis testing for PD-L1 requires many components, including antigens, antibodies, testing platforms and their associated software. The Committee noted that immunohistochemical tests can either be commercially marketed biomarkers (externally validated package and linked to an FDA approval as a companion diagnostic or complementary diagnostic) or lab developed (with potentially uncertain validation standards). The Committee noted that immunohistochemistry requires subjective assessment of staining and can be assessed with inter-reader reliability to determine stability of the subjective quantitative assessment by pathologists. The Committee noted that the tests are usually developed prior to trial outcomes data being available and are optimised to laboratory-based criteria and subsequently applied to clinical studies.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that atezolizumab has two FDA approved diagnostic tests; one using the SP263 antibody, and one using the SP142 antibody. The Committee noted that the use of SP263 for lung cancer was based on IMpower010, and that this trial was underpowered to infer the utility of PD-L1 stain percentage as a predictor of disease-free survival using this assay. The Committee noted however that there was high test-retest reliability, in that, if there was a negative test, resampling would not result in a positive result.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that evidence for the use of the SP142 assay is based on the IMpower110 trial where it was reported that PD-L1 expression in ≥ 50% of tumour cells or ≥10 tumour infiltrating immune cells determined by the SP142 assay may be associated with enhanced overall survival with atezolizumab in NSCLC patients.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the difference between the SP142 assay and the SP263 assay may be due to the difference in evidential threshold requirements for companion versus complimentary tests, and that these tests may select for different populations.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the approved antibody for pembrolizumab is the 22C3 assay. The Committee considered that based on the BLUEPRINT study (<a href=""https://pubmed.ncbi.nlm.nih.gov/27913228/"" target=""_blank"">Hirsch et al. J Thorac Oncol. 2017;12:208-22</a>), the SP263 and 22C3 assays are largely interchangeable. However, the Committee noted that none of the immunohistochemistry assays have been validated with other scoring systems and that they are sensitive to the assay package which may have commercial implications for replication.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that different assays define different population sizes, with the least sensitive assay (SP142) defining the smallest population eligible for monotherapy treatment based on PD-L1 expression. The Committee noted that there was high concordance between the SP263 and 22C3 antibodies from BLUEPRINT2 (<a href=""https://pubmed.ncbi.nlm.nih.gov/29800747/"" target=""_blank"">Taso et al. J Thorac Oncol. 2018;13:1302-11</a>), which select for larger populations and that these would likely be the antibodies used if PD-L1 testing were required for access to monotherapy.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for the efficacy and population size of atezolizumab for people with high expression of PD-L1 identified by the various antibodies would come from the evidence for the SP263 assay (<a href=""https://pubmed.ncbi.nlm.nih.gov/32997907/"" target=""_blank"">Herbst et al. N Engl J Med. 2020;383;1328-39</a> and <a href=""https://pubmed.ncbi.nlm.nih.gov/34265434/"" target=""_blank"">Jassem et al. J Thorac Oncol. 2021;16:1872-82</a>). The Committee considered that the evidence for efficacy and population size of pembrolizumab would be derived from the KEYNOTE-024 trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/33872070/"" target=""_blank"">Reck et al. J Clin Oncol. 2021;39:2339-49</a>).</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was not aware of any evidence that any given antibody works differently across different ethnicities and populations, or the prevalence of PD-L1 expression by ethnicity. The Committee considered that either atezolizumab or pembrolizumab would likely provide a similar benefit in first line monotherapy, but that this efficacy is derived from the population size inferred from the relevant companion diagnostic.</p><h3><br></h3><h3><em>PD-L1 testing and implications</em></h3><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence for testing in these cases is tied to specific devices and instrumentation with explicit external criteria for scoring, which a lab developed test may not necessarily achieve. The Committee noted that funding an ICI treatment tied to a specific test would require testing centres to be locked into infrastructure development for that particular test. The Committee noted that although some assays may be interchangeable, the performance of validated antibodies with other scoring systems is unknown. The Committee noted that if centres do not commit to the currently validated tests, and instead developed their own or used other laboratory developed tests, then the extent to which the process has been validated would be up to the individual laboratory, which may lead to variation between centres.\xa0</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted a systematic review and meta-analysis comparing biomarker modalities for predicting response to PD-L1 checkpoint inhibitors for ten different solid tumour types (<a href=""https://pubmed.ncbi.nlm.nih.gov/31318407/"" target=""_blank"">Lu et al. JAMA Oncol. 2019;5:1195-1204</a>). The Committee noted that when each modality was evaluated with summary receiver operating characteristic (sROC) curves, PD-L1 immunohistochemistry, regardless of antibody used, had an area under the curve score of 0.65 (p &lt; .001). The Committee considered that this indicated that immunohistochemical testing as a predictor of response to an ICI may be limited.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a meta-analysis of individual-level data from 14 randomised clinical trials to investigate the clinical significance of PD-L1 expression scores on overall survival (<a href=""https://pubmed.ncbi.nlm.nih.gov/35050777/"" target=""_blank"">Arfe et al. JCO Precis Oncol. 2020;4:1196-1206</a>). The Committee considered that higher staining may not necessarily be predictive of response, but rather a slightly longer overall survival than those with low or no staining.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that current evidence supports that some antibodies used in immunohistochemistry are more sensitive than others (meaning that populations eligible for treatment would differ between tests), and that the scoring systems include different elements and have often not been cross-compared with different antibodies. The Committee also considered that the evidence supporting the scoring systems as being predictive of an individual’s response is weak but noted that by FDA and EMA regulatory standards these define treatment-eligible populations.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, generally, evidence for predictive benefit of immunohistochemical assays for ICI agents is limited, and that evidence for differing sensitivity and specificity of each antibody is of moderate to good quality. The Committee noted that less sensitive assays define smaller populations. The Committee considered that the evidence supporting the value of PD-L1 testing for clinical decision making is limited, but that this inference would benefit from the reporting of outcomes for people with high expression of PD-L1 compared to those with no expression of PD-L1 in the relevant trials. The Committee considered that the primary benefit of PD-L1 testing would occur when used in conjunction with an individual’s performance status to inform treatment decision making (ie whether or not they should receive ICI monotherapy or chemotherapy).</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">April 2022</a>, CTAC noted the sub-group analysis of the patient population with PD-L1 1-49% in KEYNOTE 042 indicated minimal benefit from pembrolizumab therapy and the benefit seen in the PD-L1 &gt;1% cohort was skewed by the significant benefit seen from the PD-L1 &gt;50% cohort.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in New Zealand, MedSafe does not require a specific test to be used with ICIs, simply a “validated test”, but that the language specific to each scoring system is used for each agent, which theoretically ties the ICI to its companion or complimentary diagnostic. The Committee noted that it is unclear whether or not the same holds for the identified scoring system associated with each validated test. The Committee considered that the definition of a validated test in the New Zealand context is unclear. The Committee considered that requiring infrastructure and skill development around specific testing has short term implications in terms of which ICI agents are used, but also in the long term if other ICIs are funded in future which may require a different diagnostic test.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, if either pembrolizumab or atezolizumab were funded in this setting, there would be benefit in the supplier offering access to testing in the short term but noted that this may mean that testing centres are locked into using specific testing platforms in the long term. The Committee considered it important that the validation of an in-house lab test would be derived from its ability to identify the same population as the relevant complimentary/companion diagnostics.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that there may be variable access to diagnostic biopsy procedures in New Zealand currently, primarily those with less access to tertiary hospitals, but that Pharmac’s ability to impact this inequity was limited. The Committee considered that, in addition to access to PD-L1 testing, access to diagnostic biopsy procedures (and the obtaining of sufficient tissue amounts) to enable the testing may present a barrier to accessing monotherapy. The Committee considered that, in the absence of having available tissue from biopsy, it may be appropriate to offer individuals first-line ICI monotherapy for NSCLC if they are not fit to receive combination with chemotherapy. The Committee considered that overall, approximately 10% would not be able to undergo the biopsy, and that this group would need to be accounted for in population number estimates.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the use of immunotherapy in individuals with EGFR or ALK activating mutations would not be evidence based. The Committee however considered that confirmation of EGFR and ALK activating mutations would be sought if possible. The Committee considered that it was uncertain of the sequence of testing if there was a small volume of tissue obtained from biopsy, however this could be confirmed with pathologists and would likely vary across the country in the absence of national alignment.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that given the limited infusion capacity across the country, treatment schedules and therefore dosing frequency are important and that this should be considered beyond the immediate cost attributable to this variation during evaluation. The Committee considered that the relative shelf life and stability of the agent was an important consideration and that the value of extended shelf life and stability was of particular importance for smaller centres.\xa0</p>', 'fs': '<h3><em>Background</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009rmyy/p001521"" target=""_blank"">atezolizumab</a> and <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pu56/p000583"" target=""_blank"">pembrolizumab</a> have been previously considered as first line monotherapy treatment for NSCLC, and that both have previously received high funding recommendations from the Cancer Treatments Advisory Committee (CTAC).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">April 2022</a>, CTAC provided advice to Pharmac regarding commercial options for stage IV lung cancer treatments. The Committee noted at the April 2022 meeting, the available evidence and that it remained appropriate to consider that atezolizumab and pembrolizumab provide the same, or similar, health benefit for first line NSCLC monotherapy, such that funding of either agent in this line of therapy would be clinically appropriate. The Committee also considered at the April 2022 meeting that it was appropriate to assess previously assessed ICI agents as having a class effect for the purpose of enabling listing.</p><h3><br></h3><h3><em>Pembrolizumab and atezolizumab monotherapy</em></h3><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted additional follow-up data for pembrolizumab first-line monotherapy (<a href=""https://pubmed.ncbi.nlm.nih.gov/33872070/"" target=""_blank"">Reck et al. J Clin Oncol. 2021;39:2339-49</a>; <a href=""https://jitc.bmj.com/content/9/Suppl_2/A390"" target=""_blank"">de Castro et al. J Immunother Cancer. 2021; 0.1136/jitc-2021-SITC2021.363</a>), and atezolizumab first line monotherapy (<a href=""https://pubmed.ncbi.nlm.nih.gov/34265434/"" target=""_blank"">Jassem et al. J Thorac Oncol. 2021;16:1872-82</a>). The data reviewed for both included three-year follow-up data for atezolizumab and five-year follow-up data for pembrolizumab.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Phase III randomised controlled trials often assume a baseline hazard ratio (HR), and that the proportional change in hazard stays the same over time, so that theoretically the hazard ratios are the same at all time points which does not account for a time-treatment interaction. The Committee noted that deviations from proportional hazards are common for immunotherapy trials (57% of 263 trials studied), with hazard ratios dropping over time (<a href=""https://pubmed.ncbi.nlm.nih.gov/31345838/"" target=""_blank"">Rahman et al. Clin Cancer Res. 2019;25:6339-45</a>). The Committee noted that the changes in HR over time with immunotherapies is further confounded by cross-over within the trial and subsequent therapies.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the longer-term data from KEYNOTE-024 shows a smaller percentage benefit than the proportional hazard ratio would imply, but that there may be a small, yet undefined subpopulation with a longer-term benefit. The Committee also noted that earlier exposure to immunotherapy shows a greater benefit than those who received chemotherapy and then crossed over to pembrolizumab (ie the hazard ratio advantage for immunotherapy increases with time).</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the longer-term follow-up data for atezolizumab in Impower110 reported around 20% of patients experienced long term survival and considered this similar to the long-term results reported for pembrolizumab.</p><h3><br></h3><h3><em>Selectivity and specificity of PD-L1 antibodies</em></h3><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that immunohistochemical analysis testing for PD-L1 requires many components, including antigens, antibodies, testing platforms and their associated software. The Committee noted that immunohistochemical tests can either be commercially marketed biomarkers (externally validated package and linked to an FDA approval as a companion diagnostic or complementary diagnostic) or lab developed (with potentially uncertain validation standards). The Committee noted that immunohistochemistry requires subjective assessment of staining and can be assessed with inter-reader reliability to determine stability of the subjective quantitative assessment by pathologists. The Committee noted that the tests are usually developed prior to trial outcomes data being available and are optimised to laboratory-based criteria and subsequently applied to clinical studies.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that atezolizumab has two FDA approved diagnostic tests; one using the SP263 antibody, and one using the SP142 antibody. The Committee noted that the use of SP263 for lung cancer was based on IMpower010, and that this trial was underpowered to infer the utility of PD-L1 stain percentage as a predictor of disease-free survival using this assay. The Committee noted however that there was high test-retest reliability, in that, if there was a negative test, resampling would not result in a positive result.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that evidence for the use of the SP142 assay is based on the IMpower110 trial where it was reported that PD-L1 expression in ≥ 50% of tumour cells or ≥10 tumour infiltrating immune cells determined by the SP142 assay may be associated with enhanced overall survival with atezolizumab in NSCLC patients.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the difference between the SP142 assay and the SP263 assay may be due to the difference in evidential threshold requirements for companion versus complimentary tests, and that these tests may select for different populations.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the approved antibody for pembrolizumab is the 22C3 assay. The Committee considered that based on the BLUEPRINT study (<a href=""https://pubmed.ncbi.nlm.nih.gov/27913228/"" target=""_blank"">Hirsch et al. J Thorac Oncol. 2017;12:208-22</a>), the SP263 and 22C3 assays are largely interchangeable. However, the Committee noted that none of the immunohistochemistry assays have been validated with other scoring systems and that they are sensitive to the assay package which may have commercial implications for replication.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that different assays define different population sizes, with the least sensitive assay (SP142) defining the smallest population eligible for monotherapy treatment based on PD-L1 expression. The Committee noted that there was high concordance between the SP263 and 22C3 antibodies from BLUEPRINT2 (<a href=""https://pubmed.ncbi.nlm.nih.gov/29800747/"" target=""_blank"">Taso et al. J Thorac Oncol. 2018;13:1302-11</a>), which select for larger populations and that these would likely be the antibodies used if PD-L1 testing were required for access to monotherapy.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for the efficacy and population size of atezolizumab for people with high expression of PD-L1 identified by the various antibodies would come from the evidence for the SP263 assay (<a href=""https://pubmed.ncbi.nlm.nih.gov/32997907/"" target=""_blank"">Herbst et al. N Engl J Med. 2020;383;1328-39</a> and <a href=""https://pubmed.ncbi.nlm.nih.gov/34265434/"" target=""_blank"">Jassem et al. J Thorac Oncol. 2021;16:1872-82</a>). The Committee considered that the evidence for efficacy and population size of pembrolizumab would be derived from the KEYNOTE-024 trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/33872070/"" target=""_blank"">Reck et al. J Clin Oncol. 2021;39:2339-49</a>).</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was not aware of any evidence that any given antibody works differently across different ethnicities and populations, or the prevalence of PD-L1 expression by ethnicity. The Committee considered that either atezolizumab or pembrolizumab would likely provide a similar benefit in first line monotherapy, but that this efficacy is derived from the population size inferred from the relevant companion diagnostic.</p><h3><br></h3><h3><em>PD-L1 testing and implications</em></h3><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence for testing in these cases is tied to specific devices and instrumentation with explicit external criteria for scoring, which a lab developed test may not necessarily achieve. The Committee noted that funding an ICI treatment tied to a specific test would require testing centres to be locked into infrastructure development for that particular test. The Committee noted that although some assays may be interchangeable, the performance of validated antibodies with other scoring systems is unknown. The Committee noted that if centres do not commit to the currently validated tests, and instead developed their own or used other laboratory developed tests, then the extent to which the process has been validated would be up to the individual laboratory, which may lead to variation between centres.\xa0</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted a systematic review and meta-analysis comparing biomarker modalities for predicting response to PD-L1 checkpoint inhibitors for ten different solid tumour types (<a href=""https://pubmed.ncbi.nlm.nih.gov/31318407/"" target=""_blank"">Lu et al. JAMA Oncol. 2019;5:1195-1204</a>). The Committee noted that when each modality was evaluated with summary receiver operating characteristic (sROC) curves, PD-L1 immunohistochemistry, regardless of antibody used, had an area under the curve score of 0.65 (p &lt; .001). The Committee considered that this indicated that immunohistochemical testing as a predictor of response to an ICI may be limited.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a meta-analysis of individual-level data from 14 randomised clinical trials to investigate the clinical significance of PD-L1 expression scores on overall survival (<a href=""https://pubmed.ncbi.nlm.nih.gov/35050777/"" target=""_blank"">Arfe et al. JCO Precis Oncol. 2020;4:1196-1206</a>). The Committee considered that higher staining may not necessarily be predictive of response, but rather a slightly longer overall survival than those with low or no staining.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that current evidence supports that some antibodies used in immunohistochemistry are more sensitive than others (meaning that populations eligible for treatment would differ between tests), and that the scoring systems include different elements and have often not been cross-compared with different antibodies. The Committee also considered that the evidence supporting the scoring systems as being predictive of an individual’s response is weak but noted that by FDA and EMA regulatory standards these define treatment-eligible populations.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, generally, evidence for predictive benefit of immunohistochemical assays for ICI agents is limited, and that evidence for differing sensitivity and specificity of each antibody is of moderate to good quality. The Committee noted that less sensitive assays define smaller populations. The Committee considered that the evidence supporting the value of PD-L1 testing for clinical decision making is limited, but that this inference would benefit from the reporting of outcomes for people with high expression of PD-L1 compared to those with no expression of PD-L1 in the relevant trials. The Committee considered that the primary benefit of PD-L1 testing would occur when used in conjunction with an individual’s performance status to inform treatment decision making (ie whether or not they should receive ICI monotherapy or chemotherapy).</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">April 2022</a>, CTAC noted the sub-group analysis of the patient population with PD-L1 1-49% in KEYNOTE 042 indicated minimal benefit from pembrolizumab therapy and the benefit seen in the PD-L1 &gt;1% cohort was skewed by the significant benefit seen from the PD-L1 &gt;50% cohort.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in New Zealand, MedSafe does not require a specific test to be used with ICIs, simply a “validated test”, but that the language specific to each scoring system is used for each agent, which theoretically ties the ICI to its companion or complimentary diagnostic. The Committee noted that it is unclear whether or not the same holds for the identified scoring system associated with each validated test. The Committee considered that the definition of a validated test in the New Zealand context is unclear. The Committee considered that requiring infrastructure and skill development around specific testing has short term implications in terms of which ICI agents are used, but also in the long term if other ICIs are funded in future which may require a different diagnostic test.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, if either pembrolizumab or atezolizumab were funded in this setting, there would be benefit in the supplier offering access to testing in the short term but noted that this may mean that testing centres are locked into using specific testing platforms in the long term. The Committee considered it important that the validation of an in-house lab test would be derived from its ability to identify the same population as the relevant complimentary/companion diagnostics.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that there may be variable access to diagnostic biopsy procedures in New Zealand currently, primarily those with less access to tertiary hospitals, but that Pharmac’s ability to impact this inequity was limited. The Committee considered that, in addition to access to PD-L1 testing, access to diagnostic biopsy procedures (and the obtaining of sufficient tissue amounts) to enable the testing may present a barrier to accessing monotherapy. The Committee considered that, in the absence of having available tissue from biopsy, it may be appropriate to offer individuals first-line ICI monotherapy for NSCLC if they are not fit to receive combination with chemotherapy. The Committee considered that overall, approximately 10% would not be able to undergo the biopsy, and that this group would need to be accounted for in population number estimates.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the use of immunotherapy in individuals with EGFR or ALK activating mutations would not be evidence based. The Committee however considered that confirmation of EGFR and ALK activating mutations would be sought if possible. The Committee considered that it was uncertain of the sequence of testing if there was a small volume of tissue obtained from biopsy, however this could be confirmed with pathologists and would likely vary across the country in the absence of national alignment.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that given the limited infusion capacity across the country, treatment schedules and therefore dosing frequency are important and that this should be considered beyond the immediate cost attributable to this variation during evaluation. The Committee considered that the relative shelf life and stability of the agent was an important consideration and that the value of extended shelf life and stability was of particular importance for smaller centres.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee noted that Pharmac was seeking advice regarding the use of immune checkpoint inhibitors as monotherapy in the first line treatment of non-small cell lung cancer in relation to a recent Request for Proposals (RFP).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac was seeking advice particularly on testing considerations and the selectivity of various testing platforms in relation to the RFP.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee noted that Pharmac was seeking advice regarding the use of immune checkpoint inhibitors as monotherapy in the first line treatment of non-small cell lung cancer in relation to a recent Request for Proposals (RFP).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac was seeking advice particularly on testing considerations and the selectivity of various testing platforms in relation to the RFP.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 14 October 2022.', 'fs': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 14 October 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw4EUAS'}, 'Id': 'a0P2P000007Dw4EUAS', 'Event_Date__c': '2023-02-13', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 14 October 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Feb 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that either atezolizumab or pembrolizumab should be funded as monotherapy for the first line treatment of advanced non-small cell lung cancer (NSCLC) subject to the following Special Authority criteria:</p><p><strong style=""font-size: 9pt;"">Initial application - (non-small cell lung cancer first-line monotherapy)</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has not had chemotherapy for their disease in the palliative setting; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both </span></p><p><span style=""font-size: 9pt;"">5.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be used as monotherapy; and</span></p><p><span style=""font-size: 9pt;"">5.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">There is documentation confirming the disease expresses PD-L1 at a level ≥50% as determined by a validated test unless not possible to ascertain; and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG 0-2; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be used at a maximum dose of XXXX every XXX weeks (or equivalent) for a maximum of 12 weeks; and</span></p><p><span style=""font-size: 9pt;"">8.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Baseline measurement of overall tumour burden is documented clinically and radiologically.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">Renewal – (non-small cell lung cancer first line monotherapy)</strong><span style=""font-size: 9pt;""> only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a complete response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease has had a partial response to treatment; or</span></p><p><span style=""font-size: 9pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has stable disease; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains clinically appropriate and patient is benefitting from treatment; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be used at a maximum dose of XXXX every XXXX weeks (or equivalent); and</span></p><p><span style=""font-size: 9pt;"">6.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">XXXXX to be discontinued at signs of disease progression; and</span></p><p><span style=""font-size: 9pt;"">7.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment with XXXXX to cease after a total duration of 24 months from commencement (or equivalent).</span></p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee noted that Pharmac was seeking advice regarding the use of immune checkpoint inhibitors as monotherapy in the first line treatment of non-small cell lung cancer in relation to a recent Request for Proposals (RFP).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Pharmac was seeking advice particularly on testing considerations and the selectivity of various testing platforms in relation to the RFP.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<h3><em>Background</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009rmyy/p001521"" target=""_blank"">atezolizumab</a> and <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pu56/p000583"" target=""_blank"">pembrolizumab</a> have been previously considered as first line monotherapy treatment for NSCLC, and that both have previously received high funding recommendations from the Cancer Treatments Advisory Committee (CTAC).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">April 2022</a>, CTAC provided advice to Pharmac regarding commercial options for stage IV lung cancer treatments. The Committee noted at the April 2022 meeting, the available evidence and that it remained appropriate to consider that atezolizumab and pembrolizumab provide the same, or similar, health benefit for first line NSCLC monotherapy, such that funding of either agent in this line of therapy would be clinically appropriate. The Committee also considered at the April 2022 meeting that it was appropriate to assess previously assessed ICI agents as having a class effect for the purpose of enabling listing.</p><h3><br></h3><h3><em>Pembrolizumab and atezolizumab monotherapy</em></h3><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted additional follow-up data for pembrolizumab first-line monotherapy (<a href=""https://pubmed.ncbi.nlm.nih.gov/33872070/"" target=""_blank"">Reck et al. J Clin Oncol. 2021;39:2339-49</a>; <a href=""https://jitc.bmj.com/content/9/Suppl_2/A390"" target=""_blank"">de Castro et al. J Immunother Cancer. 2021; 0.1136/jitc-2021-SITC2021.363</a>), and atezolizumab first line monotherapy (<a href=""https://pubmed.ncbi.nlm.nih.gov/34265434/"" target=""_blank"">Jassem et al. J Thorac Oncol. 2021;16:1872-82</a>). The data reviewed for both included three-year follow-up data for atezolizumab and five-year follow-up data for pembrolizumab.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Phase III randomised controlled trials often assume a baseline hazard ratio (HR), and that the proportional change in hazard stays the same over time, so that theoretically the hazard ratios are the same at all time points which does not account for a time-treatment interaction. The Committee noted that deviations from proportional hazards are common for immunotherapy trials (57% of 263 trials studied), with hazard ratios dropping over time (<a href=""https://pubmed.ncbi.nlm.nih.gov/31345838/"" target=""_blank"">Rahman et al. Clin Cancer Res. 2019;25:6339-45</a>). The Committee noted that the changes in HR over time with immunotherapies is further confounded by cross-over within the trial and subsequent therapies.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the longer-term data from KEYNOTE-024 shows a smaller percentage benefit than the proportional hazard ratio would imply, but that there may be a small, yet undefined subpopulation with a longer-term benefit. The Committee also noted that earlier exposure to immunotherapy shows a greater benefit than those who received chemotherapy and then crossed over to pembrolizumab (ie the hazard ratio advantage for immunotherapy increases with time).</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the longer-term follow-up data for atezolizumab in Impower110 reported around 20% of patients experienced long term survival and considered this similar to the long-term results reported for pembrolizumab.</p><h3><br></h3><h3><em>Selectivity and specificity of PD-L1 antibodies</em></h3><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that immunohistochemical analysis testing for PD-L1 requires many components, including antigens, antibodies, testing platforms and their associated software. The Committee noted that immunohistochemical tests can either be commercially marketed biomarkers (externally validated package and linked to an FDA approval as a companion diagnostic or complementary diagnostic) or lab developed (with potentially uncertain validation standards). The Committee noted that immunohistochemistry requires subjective assessment of staining and can be assessed with inter-reader reliability to determine stability of the subjective quantitative assessment by pathologists. The Committee noted that the tests are usually developed prior to trial outcomes data being available and are optimised to laboratory-based criteria and subsequently applied to clinical studies.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that atezolizumab has two FDA approved diagnostic tests; one using the SP263 antibody, and one using the SP142 antibody. The Committee noted that the use of SP263 for lung cancer was based on IMpower010, and that this trial was underpowered to infer the utility of PD-L1 stain percentage as a predictor of disease-free survival using this assay. The Committee noted however that there was high test-retest reliability, in that, if there was a negative test, resampling would not result in a positive result.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that evidence for the use of the SP142 assay is based on the IMpower110 trial where it was reported that PD-L1 expression in ≥ 50% of tumour cells or ≥10 tumour infiltrating immune cells determined by the SP142 assay may be associated with enhanced overall survival with atezolizumab in NSCLC patients.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the difference between the SP142 assay and the SP263 assay may be due to the difference in evidential threshold requirements for companion versus complimentary tests, and that these tests may select for different populations.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the approved antibody for pembrolizumab is the 22C3 assay. The Committee considered that based on the BLUEPRINT study (<a href=""https://pubmed.ncbi.nlm.nih.gov/27913228/"" target=""_blank"">Hirsch et al. J Thorac Oncol. 2017;12:208-22</a>), the SP263 and 22C3 assays are largely interchangeable. However, the Committee noted that none of the immunohistochemistry assays have been validated with other scoring systems and that they are sensitive to the assay package which may have commercial implications for replication.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that different assays define different population sizes, with the least sensitive assay (SP142) defining the smallest population eligible for monotherapy treatment based on PD-L1 expression. The Committee noted that there was high concordance between the SP263 and 22C3 antibodies from BLUEPRINT2 (<a href=""https://pubmed.ncbi.nlm.nih.gov/29800747/"" target=""_blank"">Taso et al. J Thorac Oncol. 2018;13:1302-11</a>), which select for larger populations and that these would likely be the antibodies used if PD-L1 testing were required for access to monotherapy.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence for the efficacy and population size of atezolizumab for people with high expression of PD-L1 identified by the various antibodies would come from the evidence for the SP263 assay (<a href=""https://pubmed.ncbi.nlm.nih.gov/32997907/"" target=""_blank"">Herbst et al. N Engl J Med. 2020;383;1328-39</a> and <a href=""https://pubmed.ncbi.nlm.nih.gov/34265434/"" target=""_blank"">Jassem et al. J Thorac Oncol. 2021;16:1872-82</a>). The Committee considered that the evidence for efficacy and population size of pembrolizumab would be derived from the KEYNOTE-024 trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/33872070/"" target=""_blank"">Reck et al. J Clin Oncol. 2021;39:2339-49</a>).</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was not aware of any evidence that any given antibody works differently across different ethnicities and populations, or the prevalence of PD-L1 expression by ethnicity. The Committee considered that either atezolizumab or pembrolizumab would likely provide a similar benefit in first line monotherapy, but that this efficacy is derived from the population size inferred from the relevant companion diagnostic.</p><h3><br></h3><h3><em>PD-L1 testing and implications</em></h3><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence for testing in these cases is tied to specific devices and instrumentation with explicit external criteria for scoring, which a lab developed test may not necessarily achieve. The Committee noted that funding an ICI treatment tied to a specific test would require testing centres to be locked into infrastructure development for that particular test. The Committee noted that although some assays may be interchangeable, the performance of validated antibodies with other scoring systems is unknown. The Committee noted that if centres do not commit to the currently validated tests, and instead developed their own or used other laboratory developed tests, then the extent to which the process has been validated would be up to the individual laboratory, which may lead to variation between centres.\xa0</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted a systematic review and meta-analysis comparing biomarker modalities for predicting response to PD-L1 checkpoint inhibitors for ten different solid tumour types (<a href=""https://pubmed.ncbi.nlm.nih.gov/31318407/"" target=""_blank"">Lu et al. JAMA Oncol. 2019;5:1195-1204</a>). The Committee noted that when each modality was evaluated with summary receiver operating characteristic (sROC) curves, PD-L1 immunohistochemistry, regardless of antibody used, had an area under the curve score of 0.65 (p &lt; .001). The Committee considered that this indicated that immunohistochemical testing as a predictor of response to an ICI may be limited.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a meta-analysis of individual-level data from 14 randomised clinical trials to investigate the clinical significance of PD-L1 expression scores on overall survival (<a href=""https://pubmed.ncbi.nlm.nih.gov/35050777/"" target=""_blank"">Arfe et al. JCO Precis Oncol. 2020;4:1196-1206</a>). The Committee considered that higher staining may not necessarily be predictive of response, but rather a slightly longer overall survival than those with low or no staining.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that current evidence supports that some antibodies used in immunohistochemistry are more sensitive than others (meaning that populations eligible for treatment would differ between tests), and that the scoring systems include different elements and have often not been cross-compared with different antibodies. The Committee also considered that the evidence supporting the scoring systems as being predictive of an individual’s response is weak but noted that by FDA and EMA regulatory standards these define treatment-eligible populations.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, generally, evidence for predictive benefit of immunohistochemical assays for ICI agents is limited, and that evidence for differing sensitivity and specificity of each antibody is of moderate to good quality. The Committee noted that less sensitive assays define smaller populations. The Committee considered that the evidence supporting the value of PD-L1 testing for clinical decision making is limited, but that this inference would benefit from the reporting of outcomes for people with high expression of PD-L1 compared to those with no expression of PD-L1 in the relevant trials. The Committee considered that the primary benefit of PD-L1 testing would occur when used in conjunction with an individual’s performance status to inform treatment decision making (ie whether or not they should receive ICI monotherapy or chemotherapy).</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://pharmac.govt.nz/assets/2022-04-08-Cancer-Treatments-AC-Record.pdf"" target=""_blank"">April 2022</a>, CTAC noted the sub-group analysis of the patient population with PD-L1 1-49% in KEYNOTE 042 indicated minimal benefit from pembrolizumab therapy and the benefit seen in the PD-L1 &gt;1% cohort was skewed by the significant benefit seen from the PD-L1 &gt;50% cohort.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in New Zealand, MedSafe does not require a specific test to be used with ICIs, simply a “validated test”, but that the language specific to each scoring system is used for each agent, which theoretically ties the ICI to its companion or complimentary diagnostic. The Committee noted that it is unclear whether or not the same holds for the identified scoring system associated with each validated test. The Committee considered that the definition of a validated test in the New Zealand context is unclear. The Committee considered that requiring infrastructure and skill development around specific testing has short term implications in terms of which ICI agents are used, but also in the long term if other ICIs are funded in future which may require a different diagnostic test.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, if either pembrolizumab or atezolizumab were funded in this setting, there would be benefit in the supplier offering access to testing in the short term but noted that this may mean that testing centres are locked into using specific testing platforms in the long term. The Committee considered it important that the validation of an in-house lab test would be derived from its ability to identify the same population as the relevant complimentary/companion diagnostics.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that there may be variable access to diagnostic biopsy procedures in New Zealand currently, primarily those with less access to tertiary hospitals, but that Pharmac’s ability to impact this inequity was limited. The Committee considered that, in addition to access to PD-L1 testing, access to diagnostic biopsy procedures (and the obtaining of sufficient tissue amounts) to enable the testing may present a barrier to accessing monotherapy. The Committee considered that, in the absence of having available tissue from biopsy, it may be appropriate to offer individuals first-line ICI monotherapy for NSCLC if they are not fit to receive combination with chemotherapy. The Committee considered that overall, approximately 10% would not be able to undergo the biopsy, and that this group would need to be accounted for in population number estimates.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the use of immunotherapy in individuals with EGFR or ALK activating mutations would not be evidence based. The Committee however considered that confirmation of EGFR and ALK activating mutations would be sought if possible. The Committee considered that it was uncertain of the sequence of testing if there was a small volume of tissue obtained from biopsy, however this could be confirmed with pathologists and would likely vary across the country in the absence of national alignment.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that given the limited infusion capacity across the country, treatment schedules and therefore dosing frequency are important and that this should be considered beyond the immediate cost attributable to this variation during evaluation. The Committee considered that the relative shelf life and stability of the agent was an important consideration and that the value of extended shelf life and stability was of particular importance for smaller centres.\xa0</p>', 'Status_History__c': 'a132P000000EDPIQA4'}, 'change': None}]",Mar 2017,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2017', 'fs': 'Mar 2017', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw3uUAC'}, 'Id': 'a0P2P000007Dw3uUAC', 'Event_Date__c': '2017-03-24', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2017', 'Status_History__c': 'a132P000000ArGSQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2018', 'fs': 'Nov 2018', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw41UAC'}, 'Id': 'a0P2P000007Dw41UAC', 'Event_Date__c': '2018-11-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2018', 'Status_History__c': 'a132P000000ArYvQAK'}, 'change': None}]",Mar 2017,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2019', 'fs': 'Mar 2019', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw43UAC'}, 'Id': 'a0P2P000007Dw43UAC', 'Event_Date__c': '2019-03-02', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2019', 'Status_History__c': 'a132P000000ArcrQAC'}, 'change': None}]",Mar 2019,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-12-16-proposal-to-fund-two-new-treatments-for-people-with-advanced-non-small-cell-lung-cancer"" target=""_blank"">Consultation</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-12-16-proposal-to-fund-two-new-treatments-for-people-with-advanced-non-small-cell-lung-cancer"" target=""_blank"">Consultation</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2022', 'fs': 'Dec 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw4CUAS'}, 'Id': 'a0P2P000007Dw4CUAS', 'Event_Date__c': '2022-12-16', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-12-16-proposal-to-fund-two-new-treatments-for-people-with-advanced-non-small-cell-lung-cancer"" target=""_blank"">Consultation</a></p>', 'Formatted_Date__c': 'Dec 2022', 'Status_History__c': 'a132P000000EDCSQA4'}, 'change': None}]",Dec 2022,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw4DUAS'}, 'Id': 'a0P2P000007Dw4DUAS', 'Event_Date__c': '2023-02-07', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Feb 2023', 'Status_History__c': 'a132P000000EDSKQA4'}, 'change': None}]",Feb 2023,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': 'Notification letter: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-03-07-decision-to-fund-two-new-treatments-for-people-with-advanced-non-small-cell-lung-cancer/', 'fs': 'Notification letter: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-03-07-decision-to-fund-two-new-treatments-for-people-with-advanced-non-small-cell-lung-cancer/', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2023', 'fs': 'Mar 2023', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007Dw4FUAS'}, 'Id': 'a0P2P000007Dw4FUAS', 'Event_Date__c': '2023-03-07', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': 'Notification letter: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-03-07-decision-to-fund-two-new-treatments-for-people-with-advanced-non-small-cell-lung-cancer/', 'Formatted_Date__c': 'Mar 2023', 'Status_History__c': 'a132P000000EDSPQA4'}, 'change': None}]",Mar 2023,False,True
